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A rapid method to determine quality for placental proteomic studies is required due to varying lengths of
time between delivery and sampling in routine protocols. We developed a rapid 10 min LC-MS based
scanning method to proﬁle free peptides liberated from natural proteolytic degradation. The assay was
applied to placenta samples obtained following refrigeration for varying time periods post-delivery
(12 h, þ24 h, þ48 h and þ72 h). Analysis reveals time dependant overlapping proﬁles for groups <24
to þ48 h with greatest variation in the þ72 h group, indicating that signiﬁcant proteolysis affects tissue
integrity between 48 and 72 h.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
With increasing interest in maximising use of existing placental
sample banks for novel clinical studies, there is a need for a cheap,
rapid and reliable method to determine sample integrity over
varying periods and conditions of storage [1,2]. The aim of this
study was to provide proof of principle data for a rapid, cheap, mass
spectrometry based assay which could provide an estimate of the
degradation state of the placenta, which would be applicable to
selection and interpretation of routinely collected placentas for
future proteomic studies.
Modern molecular methods are heavily dependent on quality
assurance to support the reliability and validity of experimental
data. Biomarker discovery places extra emphasis on the need for
robust handling protocols for samples procured for biobanking, but
for many existing clinical research studies there is currently no
comprehensive high-throughput, automated assessment available
for overall protein quality [3]. Protein concentration can be esti-
mated using a protein assay (BSA, Lowry assay, Bradford assay). Ifeywood).
Ltd. This is an open access article uthe estimated yield is non-proportional to the amount of sample
used, proteins are assumed to be degraded, or absent. SDS-PAGE gel
electrophoresis can also be crudely used to estimate protein
integrity, however, unlike nucleic acids, which have an unequivocal
UV absorbance spectra and molecular weight, since proteins are
variable in size, charge and hydrophobicity, results are less
reproducible.
The issue of assessing sample integrity is of particular impor-
tance for studies of placental tissue since variation in time between
birth, transport to the laboratory, tissue processing and storage can
affect sample integrity. In clinical contexts the interval between
birth and sampling may be as much as 12 h, however for research
studies assessing transcriptome and RNA much shorter intervals
(under 45 min) are recommended [4]. These require specialist
protocols and are expensive in terms of personnel and reagents
required to stabilise the tissue. Hence in routine clinical practice or
large scale multicentre biobanking studies where the diagnostic or
processing laboratory may be distant from the delivery suite sam-
pling interval may be up to several days, especially if initial
refrigeration and triage is performed [5].
An investigation into the effects of prolonged storage interval
(over 12 h after birth) will provide novel data on the effects of annder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. PCA plot of placental free peptide analysis time points. The cluster regions of each time point are encircled. The <24 h group segregates completely
from þ48 h to þ72 h group but the <24 h period overlaps between <24 and þ 48 h. The most distinct group is the þ72 h group, which segregates from other groups.
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scientiﬁc experiments, thereby inﬂuencing which placental sam-
ples from more general collections might be useful for biomarker
studies. These data are particularly useful for large scale birth
cohort studies which may not analyse samples for some consider-
able time andwhere effects of sample handling and varying periods
of storage to guide sample collection, inclusion criteria and
downstream assay selection.
The monitoring of proteolytic degradation of intact structural
proteins has recently been proposed as a way of estimating time of
death [6,7]. A change in the proteome due to natural proteolysis
will also reﬂect in the ‘peptidome’. Therefore we have developed a
rapid and simple approach based on the methods typically used in
metabolic proﬁling [8,9] that can examine overall changes in the
peptidome that occur as a result of naturally occurring proteolytic
degradation.
2. Methods
Detailed methods are provided in Supplementary Data. Brieﬂy
the method involves the solubilisation of frozen placental tissue
samples, standardised to total protein content. Free peptides
liberated from the tissue that are potential proteolytic degradationFig. 2. Trending peptides signiﬁcantly up regulated (p < 0.05) in either the <12 h or þ72 h g
and were seen to decrease over time (Fig. 2) with the greatest observed decrease betw
and þ 72 h groups. The peptides that increase over time do not appear to be degradation p
peptides is signiﬁcantly larger (p < 0.0001) than those peptides that decrease (617.69 ± 1
proteins.products, are extracted and analysed using a triple quadrupole
mass spectrometer [10]. The data were analysed using pattern
proﬁling principle component analysis (PCA), which identiﬁes the
similarity of the free peptide proﬁles between samples. To test the
method we analysed placentas that had known intervals of <12, 24,
48 and 72 h from delivery to sampling and 80 C storage.
3. Results & discussion
Fig. 1 shows the PCA plot of 871 detected masses that were
doubly charged and not present in the tissue blank. Pooled QC runs
are clustered tightly in the middle of the plot, indicating the MS
scanning performed well. Overall, there is a gradual overlapping of
proﬁles between time points, whereas the þ72 h group appears to
cluster signiﬁcantly separately from the other groups, indicating
that it is between 48 and 72 h that the greatest change to the free
peptide composition occurs. Theþ48 h points segregate from those
<24 h and þ72 h, but with overlap with the þ24 h group. These
data suggest that there is a point between þ24 and þ 48 h where
the free peptide composition begins to change signiﬁcantly, with
more marked differences by þ72 h. Further analysis demonstrates
that the free peptide composition is complex and consists of
different peptides, some of which decrease (n ¼ 167) and someroup compared with all other time points were measured along the time point groups
een þ48 and þ72 h. The greatest increase of peptides is again between the þ48
roducts of the decreasing peptides as the average m/z (758.96 ± 211) of the increasing
60). These increasing peptides are more likely to originate from proteolysis of larger
W.E. Heywood et al. / Placenta 44 (2016) 109e111 111increase over time (n ¼ 55) compared with the ﬁrst <24 h group
(Fig. 2); these are likely representing both end products and in-
termediate products of degradation. Free peptide m/z values used
in this analysis are given as Supplementary Data.
This rapid LC-MS scanning assay shows that the free peptide
proﬁling of placental tissue samples can be used to reﬂect the integrity
of the tissue for subsequent proteomic analysis. The assay is simple to
perform and does not rely on the analysis or identiﬁcation of indi-
vidual proteins, removing the need for antibody methods. With
further development this approach may also have potential applica-
tion for other uses such as determining the timing andmechanisms of
intrauterine deaths and impact of storage duration on sample quality.
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Appendix A. Supplementary data
Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.placenta.2016.04.014.References
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